Hosshin Ananda

Introduction
Psilocybin, the psychoactive compound found in certain species of fungi, has moved from the margins of counterculture into some of the most prestigious research institutions in the world. What was once dismissed as a recreational curiosity is now the subject of trials at Johns Hopkins, Imperial College London, and the University of Miami, among others. The reason for this shift is not primarily its capacity to produce altered states of consciousness, but something more structurally significant: its demonstrated ability to promote the physical regrowth and reorganisation of neural connections.
This essay draws together the current state of research on psilocybin and neuroplasticity, with particular attention to its potential in stroke recovery, peripheral nerve damage, and the question of how it should most effectively be administered. The literature spans preclinical animal studies, emerging clinical trials, case reports, and theoretical frameworks that together constitute a genuinely serious scientific case for psilocybin as a neurological, not merely a psychiatric, medicine.

Part One: The Mechanisms of Psilocybin-Induced Neuroplasticity
The BDNF-TrkB-mTOR Pathway
At the molecular level, the most significant mechanism by which psilocybin promotes neuroplasticity is through the upregulation of brain-derived neurotrophic factor, or BDNF. Often described as the brain’s own growth hormone for neurons, BDNF governs the survival, growth, and differentiation of nerve cells, as well as the formation and strengthening of synaptic connections.
Psilocybin’s active metabolite, psilocin, binds to serotonin 5-HT2A receptors and also, crucially, directly to the TrkB receptor, which is BDNF’s primary signalling receptor. This dual action initiates a cascade through the mTOR pathway that results in rapid production of plasticity-related proteins. Research published in 2023 in Nature Neuroscience demonstrated that this TrkB binding occurs independently of the 5-HT2A serotonergic action, meaning that psilocybin is operating through at least two distinct neuroplastic mechanisms simultaneously.
The consequence of this cascade is structural: new dendritic spines grow. These are the tiny protrusions on neurons that form the physical substrate of synaptic connections. A landmark 2021 study published in Neuron by Shao and colleagues demonstrated that a single dose of psilocybin increased dendritic spine density and size in the medial prefrontal cortex, with effects still measurable weeks later. This is not a transient pharmacological effect but a lasting physical change in the architecture of the brain.
Dendritic Spine Growth and Structural Reorganisation
The significance of dendritic spine growth cannot be overstated in the context of neurological injury. When a stroke or nerve injury occurs, connections are lost. The brain does retain some capacity to form new pathways, known as neuroplasticity, but this capacity diminishes over time and is insufficient to restore full function in most cases. The question at the heart of current psilocybin research is whether pharmacological stimulation of spine growth can compensate for what natural recovery cannot achieve.
A systematic review covering 16 studies found that 15 of them demonstrated psychedelic-induced neuroplasticity. A single oral dose of psilocybin has been shown to increase dendritic spine density and size in both the medial prefrontal cortex and the hippocampus, accompanied by increased neurogenesis, the birth of new neurons, and elevated synaptic protein levels. These effects together suggest not merely the strengthening of existing connections but the creation of new ones.
A January 2026 paper in Nature Reviews Neuroscience added further precision to this picture, reporting that psilocybin triggers an activity-dependent rewiring of large-scale cortical networks in a selective rather than diffuse manner. The brain is not simply flooded with growth signals indiscriminately; specific networks are targeted in ways that appear to correspond to the functional demands of recovery.
Neuroinflammation and the Case for Psilocybin in Acquired Brain Injury
Alongside its neuroplastic effects, psilocybin has demonstrated significant anti-inflammatory properties in neural tissue. This is particularly relevant for brain and nerve injuries, where chronic inflammation is a major barrier to healing. Conventional anti-inflammatory drugs carry significant side effect profiles that limit their long-term use. Psilocybin appears to modulate neuroinflammation through distinct pathways, including effects on microglial activity, without the adverse effects associated with steroids or NSAIDs.
A 2025 preprint studying repetitive mild brain injury found that psilocybin reduced vasogenic oedema, restored normal vascular reactivity and functional connectivity, reduced phosphorylated tau accumulation, and enhanced BDNF and TrkB levels. Vascular reactivity, the capacity of blood vessels to respond appropriately to demand, is directly impaired following ischaemic injury, and its restoration in animal models is a meaningful finding for stroke research specifically.

Part Two: Psilocybin and Stroke Recovery
The Animal Evidence
The most directly relevant preclinical study for stroke was published in BMC Neuroscience in October 2024. Researchers in Taiwan used a rat model of ischaemic stroke and administered psilocybin in the early post-stroke period. The results were striking: psilocybin reduced the area of brain tissue destroyed by the stroke, improved locomotor behaviour in the animals, and did so through a mechanism that was confirmed to be BDNF-dependent. When TrkB, the BDNF receptor, was pharmacologically blocked, the neuroprotective effects disappeared, confirming that the BDNF pathway is not merely correlated with recovery but causally responsible for it.
This study was partially funded by a collaboration between Taiwan’s National Health Research Institutes and a Canadian company, PharmaTher Inc., which has a cooperative agreement to develop psilocybin as a treatment for neurodegenerative disorders. The involvement of institutional and commercial research investment signals that this is not fringe work.
The Critical Period Hypothesis
One of the most conceptually important ideas to emerge from recent psychedelic neuroscience is the notion of the critical period: a window of heightened neuroplasticity that exists during development and, in diminished form, immediately after injury. In standard stroke rehabilitation, much of the spontaneous recovery that occurs happens within the first three months, after which the brain’s plasticity decreases substantially and recovery plateaus.
A 2025 paper published in the journal Brain argued that psilocybin may have a unique capacity to reopen these critical periods, restoring to the injured or chronically affected brain a state of heightened receptivity to change that was previously thought to be permanently closed. This hypothesis draws on earlier work by Gul Dolen at Johns Hopkins, who demonstrated in animal studies that psychedelics can reopen the social reward learning critical period in adult mice, a finding with profound implications for any condition involving the loss of previously established neural function.
If this hypothesis holds in humans, it would mean that stroke survivors years or even decades after their event might be able to recover function that current rehabilitation medicine considers beyond reach. This is not a modest claim, and the scientific community is appropriately cautious about it. But it is the hypothesis that underlies the most significant clinical development in this field.
The Johns Hopkins Trial: PHATHOM
In June 2025, Johns Hopkins announced the launch of the first Phase 1 clinical trial investigating psilocybin for stroke recovery. The trial, formally titled Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability (PHATHOM), is led by three of the most respected names in stroke and psychedelic neuroscience: Gul Dolen, Steve Zeiler, and John Krakauer.
The trial investigates whether combining a supervised psilocybin session with digitally enhanced physical therapy can reopen neuroplastic windows and improve motor function in chronic stroke patients, those whose recovery has already plateaued. The licensed intellectual property underlying the trial encompasses methods for improving motor function in acute, subacute, and chronic central nervous system injury, as well as for treating focal diaschisis, the loss of function in brain regions connected to, but distant from, the primary site of damage.
As a Phase 1 trial, PHATHOM is primarily establishing safety and feasibility rather than measuring outcomes at scale. However, its existence at Johns Hopkins, with this team, represents a watershed moment. The treatment of stroke is now formally within the scope of psilocybin clinical research.

Part Three: Peripheral Nerve Damage and Neuropathic Pain
Peripheral Nerve Injury Models
Research published in the British Journal of Pharmacology in 2024 by Askey and colleagues reported that a single dose of psilocybin produced a prolonged reduction in pain-like behaviours in a mouse model of neuropathy following peripheral nerve injury. This is distinct from central nervous system injury: peripheral nerves, those outside the brain and spinal cord, have different regenerative properties and a different relationship with the serotonergic system that psilocybin primarily engages.
The proposed mechanisms for peripheral nerve effects include 5-HT2A receptor activation at both spinal and supraspinal levels, as well as the neuroplastic actions that improve functional connectivity in brain regions involved in chronic pain processing. The BDNF-mTOR-TrkB pathway, the same cascade that underlies central plasticity, has also been shown to play a significant role in both the development and persistence of neuropathic pain conditions, suggesting that psilocybin’s action on this pathway may simultaneously address the underlying nerve damage and the pain it generates.
Spinal Cord Injury: Case Evidence
A case series documented a 37-year-old man with quadriplegia following a cervical spinal cord injury sustained in a vehicular accident. This patient had lower extremity neuropathic pain unresponsive to tramadol and diazepam. Following a period of psilocybin use, he reported near total relief from neuropathic pain lasting six to eight hours per dose. After six months of microdosing, he reported sustained pain relief of 90 to 95 percent. Notably, the psilocybin also induced muscle spasms in his paralysed muscles, which he experienced as therapeutic, describing them as akin to passive exercise.
A separate published review of spinal cord injury patients and psychedelic use noted that psilocybin produces a distinctive phenomenon in this population: intense but transient muscle spasms and autonomic sensitivity, attributed to the altered serotonin receptor landscape below the level of a spinal lesion. No worsening of baseline neurological deficits was reported. This heightened sensitivity warrants careful medical supervision but does not preclude therapeutic use.
Phantom Limb Pain and Cross-Modal Reorganisation
A particularly illuminating case report described a patient with refractory phantom limb pain who had failed opioids, pregabalin, and medical cannabis. Following a single session with psilocybin, transient pain relief was achieved. Researchers then combined psilocybin with mirror visual feedback therapy, a technique that uses visual illusion to retrain cortical maps. The combination produced long-standing remission of the phantom limb pain. The researchers attributed this to psilocybin’s facilitation of cross-modal cortical reorganisation, meaning the compound’s neuroplastic effect enabled the brain to revise its representation of the missing limb in a way that mirror therapy alone could not achieve.
This case is significant because it demonstrates that psilocybin’s neuroplastic effect is not passive. It does not simply promote growth indiscriminately. When combined with targeted rehabilitation input, the growth appears to be directed into functionally useful pathways. This is a principle that runs through the design of the Johns Hopkins stroke trial and may be one of the most important practical insights the field has generated.

Part Four: Dosing, Protocols, and Best Approaches
The Two Regimes: Higher Dose and Microdose
The research literature and clinical practice divide psilocybin use into two substantially different regimes that operate through related but not identical mechanisms and are suited to different therapeutic aims.
Higher doses, typically in the range of 20 to 30mg of pharmaceutical psilocybin, roughly equivalent to two to five grams of dried mushroom depending on potency, are what the major clinical trials use. These doses produce the full psychedelic experience and appear to be necessary for the most robust structural neuroplastic effects. The Shao et al. study demonstrating lasting dendritic spine growth used a single meaningful dose. The rat stroke model used pharmacologically significant doses. The Johns Hopkins trial is built around supervised higher-dose sessions combined immediately with intensive rehabilitation.
Microdosing, by contrast, involves sub-perceptual doses, typically 0.1 to 0.3 grams of dried mushroom, or approximately one to three milligrams of psilocybin. At these levels, no psychedelic experience occurs. The evidence for structural neuroplasticity at microdose levels is less well established than for higher doses, but there is reason to believe that the BDNF-TrkB pathway can be activated to some degree below the perceptual threshold. The neuropathic pain case series cited earlier used a microdosing protocol over six months and achieved striking results, suggesting meaningful biological activity even at low doses.
The Tolerance Problem and Why Daily Use Fails
One of the most important practical facts about psilocybin is that it produces rapid tolerance. The serotonin 5-HT2A receptors downregulate with repeated stimulation; dose daily and within a matter of days the receptors become less responsive and the therapeutic effect diminishes substantially. This is not merely a theoretical concern but a well-documented pharmacological phenomenon that makes daily microdosing counterproductive despite its intuitive appeal.
The research and the community of practitioners who have developed protocols over many years are consistent on this point: intermittent dosing is essential. Receptor sensitivity must be allowed to restore between doses, and the evidence suggests that consolidation of neuroplastic changes may occur during rest periods rather than during active dosing.
Established Microdosing Protocols
Three protocols have emerged as the most widely used and studied in the microdosing context. The Fadiman Protocol, named after researcher James Fadiman, uses a one day on, two days off schedule: dose on day one, rest on days two and three, dose again on day four. This is the most commonly researched protocol in observational studies and appears to provide adequate receptor recovery between doses.
A second approach uses two days per week, with at least two consecutive rest days between each dose day. This is slightly more conservative than the Fadiman schedule and is sometimes preferred in clinical settings where the population includes people with greater neurological vulnerability.
A third approach doses every other day, though some practitioners consider this the minimum rest interval and prefer the additional recovery time built into the Fadiman schedule.
The consensus across protocols is that rest days are not merely practical pauses between doses but may be functionally active periods during which the brain consolidates the structural changes initiated during the dose day. Sleep in particular, during which synaptic pruning and memory consolidation occur, may be central to how psilocybin-induced changes become durably embedded.
The Case for Combined Approaches: Dose Plus Rehabilitation
Perhaps the most important insight to emerge from the current literature is that psilocybin’s neuroplastic effects are most powerful when combined with targeted rehabilitation during the period of heightened plasticity following a dose. This is the fundamental design principle of the Johns Hopkins PHATHOM trial: psilocybin is not being given as a standalone treatment but as a means of opening a window, during which digitally enhanced physical therapy drives new neural connections into functional patterns.
The same principle was demonstrated in the phantom limb case: psilocybin alone produced transient relief; psilocybin combined with mirror visual feedback produced lasting remission. Early animal research at Stony Brook University combined LSD with neurotrophin-3 in paralysed rats and found that the combination produced far greater recovery than either substance alone. The implication across all of these findings is consistent: neuroplastic stimulation without directed activity may produce structural change without functional gain. The two must work together.
For stroke survivors in particular, this suggests that any future clinical application of psilocybin will almost certainly be paired with physiotherapy, occupational therapy, or speech and language therapy timed to coincide with the neuroplastic window following a supervised dose. The drug, in this model, is not the treatment. It is the key that unlocks the door through which rehabilitation can walk.

Conclusion
The research into psilocybin and neuroplasticity has moved with unusual speed from the laboratory bench to Phase 1 human trials. The molecular mechanisms are now well characterised: psilocybin upregulates BDNF, promotes dendritic spine growth, reduces neuroinflammation, and appears to reopen critical periods of plasticity that are normally closed in the adult or injured brain. These are not marginal effects but structural changes measurable weeks after a single dose.
For stroke survivors, the evidence base is at an early but genuinely promising stage. Animal studies show direct neuroprotection following ischaemic injury. The critical period hypothesis offers a theoretical framework for why psilocybin might benefit even those whose recovery has long since plateaued. And the Johns Hopkins PHATHOM trial represents the formal entry of stroke rehabilitation into the scope of psilocybin clinical medicine.
For those with nerve damage, the picture is similarly early but coherent. Peripheral nerve injury models show lasting reductions in neuropathic pain behaviour. Human case reports, while anecdotal, describe effects that exceed what conventional medicine has achieved. The common thread is the BDNF pathway, which appears to operate in peripheral as well as central neuroplasticity.
On the question of dosing, the evidence points in a clear direction. Higher supervised doses produce the most robust neuroplastic effects and are the basis of current clinical trials. Microdosing, administered intermittently on protocols such as the Fadiman schedule, appears to produce meaningful biological effects at sub-perceptual levels, particularly for chronic pain and mood, but the structural rewiring evidence is stronger for higher doses. Daily dosing is counterproductive due to rapid receptor tolerance and should be avoided.
Most importantly, the evidence consistently suggests that psilocybin works best not as a passive treatment but as a facilitator of active rehabilitation. The neuroplastic window it opens is an opportunity; what determines the functional outcome is what is done within that window. For any person with acquired neurological damage considering this territory, that principle, psilocybin as the key and rehabilitation as the door, may be the most clinically important insight the current research has to offer.

Key Sources: Shao et al., Neuron, 2021; Yu et al., BMC Neuroscience, 2024; Askey et al., British Journal of Pharmacology, 2024; Yang, Li, Chen, Brain, 2025; Johns Hopkins PHATHOM Trial, ClinicalTrials.gov, 2025; Weiss et al., Brain Sciences, 2025; Sonda et al., Trends in Pharmacological Sciences, 2025; Jiang et al., Cell, 2025; Moliner et al., Nature Neuroscience, 2023.